Opioid Use Disorder

Opioid Use Disorder Market Outlook

The global Opioid Use Disorder (OUD) market is expected to reach approximately USD 4.5 billion by 2025, growing at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2035. This growth is fueled by the increasing prevalence of opioid addiction, which has become a public health crisis in many regions, particularly in North America. As awareness of opioid dependence rises and more healthcare professionals recognize the importance of effective treatment options, the OUD market is poised for significant expansion. Furthermore, the development of new medications and treatment protocols, along with government initiatives aimed at combating opioid misuse, are expected to further bolster market growth. The ongoing research focused on improving treatment regimens and reducing the stigma associated with OUD also plays a crucial role in the market's upward trajectory.

Growth Factor of the Market

The Opioid Use Disorder market is experiencing rapid growth due to several contributing factors. Firstly, the increasing incidence of opioid addiction has prompted healthcare providers to seek effective treatment options, thus driving demand for medication-assisted treatments. The growing awareness about the importance of early intervention and comprehensive treatment approaches is also promoting the acceptance and utilization of various therapeutic options available in the market. Additionally, the government and regulatory bodies have taken a proactive stance in addressing the opioid crisis, implementing strategies that support treatment accessibility and affordability, which in turn promotes market growth. The integration of digital health solutions into treatment plans is another factor that has gained traction, making it easier for patients to access care. Lastly, ongoing research and development in this field are paving the way for innovative treatments that can effectively address the complexities of opioid dependence.

Key Highlights of the Market

• The global OUD market is projected to reach USD 4.5 billion by 2025.
• North America dominates the market, accounting for over 40% of the total share.
• Medication-assisted treatment is the leading application segment, driven by the efficacy of drug therapies.
• Buprenorphine is expected to witness the highest growth rate among product types.
• Government initiatives are essential in promoting treatment accessibility and addressing stigma associated with OUD.

By Product Type

Methadone:

Methadone is a long-acting opioid agonist commonly used in the treatment of opioid use disorder. It helps stabilize patients by reducing withdrawal symptoms and cravings associated with the cessation of opioid use. This medication is usually administered as part of a comprehensive treatment plan that includes counseling and psychosocial support. Methadone maintenance therapy has been shown to improve treatment retention and reduce illicit opioid use. As the understanding of opioid dependence evolves, methadone continues to be a cornerstone therapeutic option, particularly in outpatient settings where long-term management is needed.

Buprenorphine:

Buprenorphine is a partial opioid agonist that has gained popularity due to its effectiveness in reducing opioid cravings and withdrawal symptoms. It has a "ceiling effect," which reduces the risk of overdose compared to full agonists. Buprenorphine can be prescribed in office settings, which enhances accessibility for patients seeking treatment. The medication can be offered in combination with naloxone to prevent misuse, making it a preferred choice in outpatient settings. Furthermore, the rising awareness of buprenorphine's benefits in medication-assisted treatment programs is contributing to its increasing adoption across various demographics.

Naltrexone:

Naltrexone is an opioid antagonist used to prevent relapse in individuals who have previously undergone detoxification from opioids. Unlike methadone and buprenorphine, which are used during active addiction, naltrexone is prescribed after a person has completed detoxification, as it blocks the euphoric effects of opioids. The availability of extended-release injectable formulations has facilitated compliance, as patients need to receive the medication only once a month. Its growing acceptance as an effective option for relapse prevention is reflected in increased demand, especially among those committed to long-term recovery.

Suboxone:

Suboxone is a combination of buprenorphine and naloxone, designed to treat opioid addiction while minimizing the potential for misuse. The inclusion of naloxone helps counteract the effects of buprenorphine when taken intravenously, thereby discouraging abuse. This formulation is often favored in medication-assisted treatment programs due to its dual-action mechanism and ease of administration. As more physicians become certified to prescribe Suboxone and patient awareness grows, this product's market share is expected to increase significantly over the coming years.

Heroin:

Heroin, while illegal and associated with significant health risks, is still a substance that many individuals struggle with, leading to the necessity for effective treatment options. The heroin market reflects the dire need for interventions aimed at reducing its use and associated harm. The shift towards more comprehensive treatment models that include harm reduction strategies, like supervised injection sites and access to naloxone, aims to address the crisis surrounding heroin addiction. Despite the illicit nature of the substance, understanding its role in the opioid epidemic is crucial for formulating effective public health responses and treatment protocols.

By Application

Medication-Assisted Treatment:

Medication-assisted treatment (MAT) is a cornerstone of addressing opioid use disorder, combining pharmacotherapy with counseling and behavioral therapies. This approach has proven effective in reducing opioid use and enhancing patient outcomes. The integration of MAT into treatment plans is increasingly recognized as the gold standard for managing opioid dependence. As healthcare professionals and policymakers work to destigmatize opioid addiction and promote comprehensive treatment options, MAT's market share is expected to grow significantly. The increasing funding and support for programs that incorporate MAT are also contributing to its expansion, reflecting a shift in public perception towards treatment accessibility.

Detoxification:

Detoxification is the initial step in the treatment of opioid use disorder, aimed at safely managing withdrawal symptoms and cravings. This process can be medically supervised or conducted in outpatient settings, depending on the severity of the addiction. Effective detoxification sets the foundation for further treatment approaches such as MAT. The demand for detox services is on the rise as public awareness of opioid addiction increases, leading to more individuals seeking help. The focus on integrated care models that address both the physical and psychological aspects of addiction is driving improvements in detoxification protocols and enhancing patient experiences.

Pain Management:

Pain management is a significant application area within the opioid use disorder market. Many individuals with chronic pain may inadvertently develop opioid dependencies due to long-term use of prescribed medications. The recognition of this overlap has prompted healthcare providers to explore safer alternatives and implement more effective pain management strategies. As a result, the market for pain management solutions that incorporate non-opioid therapies and multimodal approaches is expanding. Additionally, the ongoing research into alternative pain management therapies, such as physical therapy and cognitive-behavioral therapy, seeks to minimize reliance on opioids and address the root causes of chronic pain.

Others:

The "Others" category encompasses a variety of applications related to opioid use disorder treatment, including rehabilitation programs and community-based initiatives that support recovery. These programs often focus on holistic approaches that integrate mental health support, life skills training, and social reintegration efforts. The rising prevalence of OUD has prompted the development of innovative recovery programs tailored to meet the diverse needs of individuals struggling with addiction. As these programs gain visibility and funding, they contribute to the overall effectiveness of treatment strategies and improve long-term recovery outcomes.

By Distribution Channel

Hospitals:

Hospitals play a crucial role in the distribution of treatment options for opioid use disorder. They provide comprehensive care that includes detoxification, medication-assisted treatment, and follow-up support services. The hospital setting allows for close monitoring of patients undergoing treatment, ensuring immediate intervention if complications arise. Moreover, hospitals often collaborate with community resources to facilitate ongoing care and support for individuals seeking recovery after discharge. As healthcare systems increasingly recognize the importance of addressing opioid dependency, hospital-based programs are expected to receive greater investment and focus in the coming years.

Specialty Clinics:

Specialty clinics dedicated to treating opioid use disorder have emerged as vital components of the healthcare landscape. These clinics typically offer a range of evidence-based treatment options, including medication-assisted therapy, counseling, and support groups. The personalized and focused approach of specialty clinics allows for tailored treatment plans that address individual patient needs. As more patients seek targeted care for opioid dependency, the demand for these clinics is expected to rise. Their role in improving treatment retention and reducing stigma associated with opioid addiction is vital to the overall success of recovery efforts.

Retail Pharmacies:

Retail pharmacies are increasingly recognized as critical distribution channels for opioid addiction treatments, particularly for medications like buprenorphine and naltrexone. The accessibility of these medications at pharmacies facilitates early intervention and supports adherence to treatment regimens. Additionally, initiatives to train pharmacists in addiction treatment and recovery support are enhancing the role of retail pharmacies in the healthcare continuum. As patients seek convenience and confidentiality in accessing medications, retail pharmacies are becoming essential partners in addressing the opioid crisis and promoting healthier communities.

E-Commerce:

The rise of e-commerce has transformed the landscape for opioid use disorder treatment by providing patients with access to medications and support resources online. Telemedicine and online pharmacy models have gained traction, particularly during the COVID-19 pandemic, as individuals seek safe and convenient options for receiving care. E-commerce platforms enable patients to access medication-assisted treatments without the stigma often associated with in-person visits. As regulations around telehealth continue to evolve, the role of e-commerce in the OUD market is likely to expand, offering new opportunities for improving treatment accessibility.

Others:

The "Others" category includes a variety of distribution channels that contribute to the delivery of treatment for opioid use disorder. These may encompass community health organizations, outreach programs, and mobile treatment units that target underserved populations. By providing care in various settings, including schools and community centers, these channels help raise awareness of addiction issues and promote access to treatment. The growing recognition of the need for diverse distribution strategies is critical to addressing the opioid crisis effectively and reaching individuals who may be hesitant to seek help through traditional healthcare pathways.

By Ingredient Type

Oxycodone:

Oxycodone, a powerful opioid pain reliever, is frequently prescribed for moderate to severe pain management. Its potential for addiction and misuse has raised concerns, leading to increased scrutiny in prescribing practices. As awareness of opioid dependency grows, the focus on minimizing the misuse of oxycodone is becoming paramount. Healthcare professionals are now more inclined to explore alternative pain management strategies and non-opioid medications, which influences the overall market dynamics. Increasingly, oxycodone is being monitored closely, with steps taken to implement stricter guidelines and promote accountability in its prescription and use.

Hydrocodone:

Hydrocodone is another commonly prescribed opioid used to alleviate pain. Similar to oxycodone, hydrocodone has a high potential for dependence and abuse, prompting increased regulatory measures and public health campaigns aimed at reducing misuse. The growing awareness of the consequences of opioid addiction has led to a decline in hydrocodone prescriptions in many regions, as healthcare providers seek to prioritize patient safety. However, the demand for hydrocodone remains, particularly among patients with chronic pain who have not found relief through other means. As a result, the market for hydrocodone remains significant, albeit under closer scrutiny.

Fentanyl:

Fentanyl is a potent synthetic opioid that has gained notoriety for its association with a significant increase in overdose deaths. While it is effective for pain management, its high potency makes it particularly dangerous, leading to a surge in illicit fentanyl use. In response to the opioid crisis, healthcare providers are focusing on developing safer alternatives and implementing stricter prescribing guidelines for fentanyl. The ongoing discussions around balancing the need for pain relief with the risks associated with fentanyl use will continue to shape its role in the opioid use disorder market in the coming years.

Codeine:

Codeine is a less potent opioid often used in combination with other medications to treat mild to moderate pain. While it is less frequently associated with severe addiction issues compared to stronger opioids, there is still a risk of dependence, particularly in individuals using it long-term. The market for codeine reflects the need for safer prescribing practices and more awareness about the potential for abuse. In light of the opioid crisis, there is a growing emphasis on educating both healthcare providers and patients about the risks associated with codeine and similar medications, ultimately influencing market dynamics.

Morphine:

Morphine is a well-established opioid analgesic used to manage severe pain. It remains an essential part of pain management protocols in various healthcare settings, particularly for patients undergoing surgery or receiving palliative care. While morphine is effective, its potential for addiction necessitates careful monitoring and regulation. The increasing emphasis on individualized pain management strategies is driving the exploration of morphine alternatives, although it continues to be a vital option for many patients who require strong pain relief. As the healthcare landscape evolves, morphine will be evaluated alongside other treatment options in the context of opioid stewardship and responsible prescribing practices.

By Region

North America holds the largest share of the Opioid Use Disorder market, accounting for over 40% of the total revenue. The region's substantial market size is largely attributed to the ongoing opioid epidemic that has prompted urgent action from healthcare providers, policymakers, and communities. The increasing prevalence of opioid addiction coupled with rising awareness of treatment options has led to a heightened demand for medication-assisted treatments and support services. The CAGR for North America is projected to be around 7.2% over the forecast period, driven by government initiatives aimed at expanding access to care and addressing the root causes of addiction.

Europe is witnessing a growing demand for opioid use disorder treatments, largely influenced by the rising opioid abuse rates and the need for effective interventions. The European market is expected to experience significant growth, with a CAGR of approximately 5.8% from 2025 to 2035. European countries are increasingly implementing policies to improve treatment access and integrate mental health services into addiction treatment programs. Additionally, a focus on harm reduction and patient-centered care is contributing to the growth of the OUD market throughout the region. As awareness of opioid addiction spreads, the demand for comprehensive treatment solutions continues to rise.

Opportunities

The opioid use disorder market presents significant opportunities for innovation and growth as the healthcare landscape evolves. One major opportunity lies in the advancement of telehealth services, which can significantly enhance access to addiction treatment for individuals in remote or underserved areas. Telemedicine can facilitate virtual consultations, medication management, and ongoing support for patients struggling with opioid dependence, thereby reducing barriers to care. As technology continues to advance, integrating digital health solutions into treatment protocols can lead to improved patient outcomes and increased adherence to medication-assisted therapies. Furthermore, the ongoing development of novel pharmacotherapies targeting opioid dependence offers additional avenues for growth within the market.

Another promising opportunity in the opioid use disorder market is the increasing collaboration between public health organizations, governments, and private sector stakeholders to combat the opioid crisis. Heightened awareness and advocacy surrounding addiction have led to significant funding and resources allocated towards treatment and prevention programs. This collaborative effort not only aims to improve access to care but also focuses on reducing stigma and promoting a more supportive environment for individuals in recovery. As these initiatives gain momentum, the demand for effective treatment solutions is expected to rise, presenting a substantial opportunity for market players to develop and offer comprehensive strategies that meet diverse patient needs.

Threats

While the opioid use disorder market is poised for growth, several threats could hinder its expansion. One primary concern is the ongoing stigma surrounding addiction, which can prevent individuals from seeking help and accessing treatment. The societal perception of opioid use disorder as a moral failing rather than a complex medical condition can discourage those affected from pursuing necessary interventions. Additionally, the stigma can influence healthcare professionals' willingness to prescribe medication-assisted treatments, further limiting access to care. Efforts to educate the public and healthcare providers about the nature of addiction are essential to mitigating these threats and fostering a more supportive environment for individuals seeking recovery.

Another significant threat to the opioid use disorder market is the emergence of counterfeit and illicit drugs. As demand for opioid medications continues to rise, so does the market for illegal substances that mimic legitimate treatments. The proliferation of counterfeit medications poses serious risks to patient safety and can undermine the effectiveness of treatment strategies. Furthermore, the presence of potent synthetic opioids, such as fentanyl, in the illicit drug supply exacerbates the risk of overdose and complicates public health efforts to address the crisis. Combating these challenges will require concerted efforts from regulatory agencies, healthcare providers, and community organizations to ensure patient safety and promote effective treatment options.

Competitor Outlook

• Indivior PLC
• Camurus AB
• Alkermes PLC
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• PhaseBio Pharmaceuticals, Inc.
• Opiant Pharmaceuticals, Inc.
• Pfizer Inc.
• AstraZeneca PLC
• Johnson & Johnson
• AbbVie Inc.
• Insys Therapeutics, Inc.
• Hikma Pharmaceuticals PLC
• Rhythm Pharmaceuticals, Inc.
• Viridian Therapeutics, Inc.

The competitive landscape of the Opioid Use Disorder market is characterized by a mix of established pharmaceutical companies and emerging players focused on addressing the ongoing opioid crisis. Major corporations like Indivior PLC and Alkermes PLC lead the market with their innovative medication-assisted treatment options, such as Suboxone and Vivitrol, respectively. These companies have invested significantly in research and development to enhance treatment efficacy and improve patient outcomes. The competitive advantage they maintain stems from their robust product portfolios, extensive experience in the pharmaceutical industry, and established relationships with healthcare providers and regulatory agencies.

In addition to established companies, several emerging firms are entering the market, bringing fresh perspectives and novel treatment approaches to opioid use disorder. For example, PhaseBio Pharmaceuticals and Opiant Pharmaceuticals are developing innovative therapies aimed at addressing the complexities of addiction. These companies are focused on creating safer and more effective treatment options, leveraging advancements in biotechnology and pharmacology. The competition among these players fosters a dynamic market environment that drives innovation, ultimately benefiting patients seeking recovery from opioid dependency.

Furthermore, collaboration and partnerships among industry players, research institutions, and public health organizations are becoming increasingly important in the quest to combat opioid use disorder. Companies such as Johnson & Johnson and Pfizer are engaging in initiatives aimed at raising awareness and expanding access to treatment resources. The alignment of interests among various stakeholders enhances the potential for synergistic efforts to address the opioid crisis holistically. This collaborative approach not only strengthens market positions for involved companies but also contributes positively to the overall public health response.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Camurus AB
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Alkermes PLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Indivior PLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Insys Therapeutics, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hikma Pharmaceuticals PLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Viridian Therapeutics, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Opiant Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Rhythm Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 PhaseBio Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Opioid Use Disorder Market, By Application
    • 6.1.1 Medication-Assisted Treatment
    • 6.1.2 Detoxification
    • 6.1.3 Pain Management
    • 6.1.4 Others
  • 6.2 Opioid Use Disorder Market, By Product Type
    • 6.2.1 Methadone
    • 6.2.2 Buprenorphine
    • 6.2.3 Naltrexone
    • 6.2.4 Suboxone
    • 6.2.5 Heroin
  • 6.3 Opioid Use Disorder Market, By Ingredient Type
    • 6.3.1 Oxycodone
    • 6.3.2 Hydrocodone
    • 6.3.3 Fentanyl
    • 6.3.4 Codeine
    • 6.3.5 Morphine
  • 6.4 Opioid Use Disorder Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 E-Commerce
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Opioid Use Disorder Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Opioid Use Disorder market is categorized based on

By Product Type

• Methadone
• Buprenorphine
• Naltrexone
• Suboxone
• Heroin

By Application

• Medication-Assisted Treatment
• Detoxification
• Pain Management
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• E-Commerce
• Others

By Ingredient Type

• Oxycodone
• Hydrocodone
• Fentanyl
• Codeine
• Morphine

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Indivior PLC
• Camurus AB
• Alkermes PLC
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• PhaseBio Pharmaceuticals, Inc.
• Opiant Pharmaceuticals, Inc.
• Pfizer Inc.
• AstraZeneca PLC
• Johnson & Johnson
• AbbVie Inc.
• Insys Therapeutics, Inc.
• Hikma Pharmaceuticals PLC
• Rhythm Pharmaceuticals, Inc.
• Viridian Therapeutics, Inc.